Incyte Corporation vs IQIYI Inc - ADR — how do they compare? Incyte Corporation trades at $115.7 (market cap $23.11B), while IQIYI Inc - ADR trades at $1.26 (market cap $1.20B). The key difference: Incyte Corporation is far larger — about 19.3× IQIYI Inc - ADR's market cap, and Incyte Corporation is trading nearer its 52-week high, IQIYI Inc - ADR nearer its low. Which is the better fit depends on your goals.
| INCY | IQ | |
|---|---|---|
Market Cap | $23.11B | $1.20B |
Sector | Health | Media |
52-Week High | $118.52 | $2.79 |
52-Week Low | $67.38 | $0.96 |
Enterprise Value | $19.13B | $2.76B |
Trailing returns across standard periods
Latest headlines on both assets
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →iQIYI Inc is an online entertainment service provider in China. It is primarily engaged in providing a variety of services encompassing internet video, live broadcasting, online games, online literature, animations, e-commerce, and social media platform. The company produces original video content and distributes appealing professionally produced content, partner-generated content, and user-generated content. It also offers a diverse collection of internet video content that appeals to users from broad demographics. The company's revenue is generated from membership services and online advertising services. The company earns most of its revenue from China.
Read more on IQ →